Background: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was developed in 2015 to standardize reporting of salivary gland cytology, promote better communication between clinicians and institutions, and ultimately improve patient outcomes care. The current study aims to determine the cytopathological spectrum of salivary gland lesions using the Milan System for reporting in a tertiary care hospital of northeast India. Methods: Clinical data and cytology smears of salivary gland lesions diagnosed from January 2016 to May 2021 were retrieved. All the cytology smears were reviewed again and reclassified to one of the six categories after applying strict criteria given by MSRSGC. Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of FNAC to detect malignant lesions were calculated considering HPE as the gold standard. Results: A total of 57 salivary gland lesions were examined, 31 (54.38%) were males, and 26 (45.6%) were females with a median age of 34 years (range 6-70 years). Statistical analysis showed the sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy as 75%, 100%, 100%, 95%, and 95.65%, respectively. MSRSGC Category IVa was the commonest with 29 cases of pleomorphic adenoma. Conclusion: The overall diagnostic accuracy of cytologic reporting of salivary gland lesions based on Milan nomenclature in our institution was 95.65%. Our findings reflect the positive contribution of the MSRSGC towards accurately identifying the malignant lesions and thus further helping the clinicians regarding the specific management decisions.
{"title":"Cytopathological Spectrum of Salivary Gland Lesions According to Milan Reporting System: A Retrospective Study","authors":"Balmiki Datta, Michimi Daimary, Krishangee Bordoloi, Chandrama Thakuria","doi":"10.31557/apjcc.2023.8.3.465-470","DOIUrl":"https://doi.org/10.31557/apjcc.2023.8.3.465-470","url":null,"abstract":"Background: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was developed in 2015 to standardize reporting of salivary gland cytology, promote better communication between clinicians and institutions, and ultimately improve patient outcomes care. The current study aims to determine the cytopathological spectrum of salivary gland lesions using the Milan System for reporting in a tertiary care hospital of northeast India. Methods: Clinical data and cytology smears of salivary gland lesions diagnosed from January 2016 to May 2021 were retrieved. All the cytology smears were reviewed again and reclassified to one of the six categories after applying strict criteria given by MSRSGC. Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of FNAC to detect malignant lesions were calculated considering HPE as the gold standard. Results: A total of 57 salivary gland lesions were examined, 31 (54.38%) were males, and 26 (45.6%) were females with a median age of 34 years (range 6-70 years). Statistical analysis showed the sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy as 75%, 100%, 100%, 95%, and 95.65%, respectively. MSRSGC Category IVa was the commonest with 29 cases of pleomorphic adenoma. Conclusion: The overall diagnostic accuracy of cytologic reporting of salivary gland lesions based on Milan nomenclature in our institution was 95.65%. Our findings reflect the positive contribution of the MSRSGC towards accurately identifying the malignant lesions and thus further helping the clinicians regarding the specific management decisions.","PeriodicalId":502165,"journal":{"name":"Asian Pacific Journal of Cancer Care","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139364550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.31557/apjcc.2023.8.3.459-464
Endah Zuraidah, Nur Fitrianingsih Pujiano Agatha, Sarah Qanita Edwar, Supri Irianti Handayani
Background: Breast cancer is one of the most common cancer among Indonesian females. Many risk factors can increase the chance of developing breast cancer. Hormonal factor seems to play a role in many cases of breast cancer. The aim of this research is to determine the relationship between age at menarche and breast cancer in Dr. Cipto Mangunkusumo National General Hospital Jakarta in 2010-2014.Methods: The retrospective research is using cross-sectional design study with random sampling technique. There are 98 samples. The samples were taken in Archive Unit of Anatomical Pathology of FMUI with a further investigation in Medical Record Unit and Medical Department of Surgery in Dr. Cipto Mangunkusumo National General Hospital Jakarta. The data were analyzed by using chi square test then Fisher test. Results: There is no statistically significant between age at menarche and breast cancer in Dr. Cipto Mangunkusumo National General Hospital Jakarta in 2010-2014 (p>0,05). The results of this study also indicate that the 40-49 year age group is the age group that has the highest number of breast cancer cases compared to other age groups. The age at first menstruation > 12 years was associated with the highest frequency of breast cancer cases in the study population. Conclusion: The age at first menstruation statistically did not significantly affect breast cancer incidence in Dr. Cipto Mangunkusumo Hospital Jakarta in 2010-2014. However, further research using different study designs and larger sample sizes required.
{"title":"Correlation between Age at First Menarche and Breast Cancer in Dr. Cipto Mangunkusumo National General Hospital Jakarta in 2010-2014","authors":"Endah Zuraidah, Nur Fitrianingsih Pujiano Agatha, Sarah Qanita Edwar, Supri Irianti Handayani","doi":"10.31557/apjcc.2023.8.3.459-464","DOIUrl":"https://doi.org/10.31557/apjcc.2023.8.3.459-464","url":null,"abstract":"Background: Breast cancer is one of the most common cancer among Indonesian females. Many risk factors can increase the chance of developing breast cancer. Hormonal factor seems to play a role in many cases of breast cancer. The aim of this research is to determine the relationship between age at menarche and breast cancer in Dr. Cipto Mangunkusumo National General Hospital Jakarta in 2010-2014.Methods: The retrospective research is using cross-sectional design study with random sampling technique. There are 98 samples. The samples were taken in Archive Unit of Anatomical Pathology of FMUI with a further investigation in Medical Record Unit and Medical Department of Surgery in Dr. Cipto Mangunkusumo National General Hospital Jakarta. The data were analyzed by using chi square test then Fisher test. Results: There is no statistically significant between age at menarche and breast cancer in Dr. Cipto Mangunkusumo National General Hospital Jakarta in 2010-2014 (p>0,05). The results of this study also indicate that the 40-49 year age group is the age group that has the highest number of breast cancer cases compared to other age groups. The age at first menstruation > 12 years was associated with the highest frequency of breast cancer cases in the study population. Conclusion: The age at first menstruation statistically did not significantly affect breast cancer incidence in Dr. Cipto Mangunkusumo Hospital Jakarta in 2010-2014. However, further research using different study designs and larger sample sizes required.","PeriodicalId":502165,"journal":{"name":"Asian Pacific Journal of Cancer Care","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139364405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.31557/apjcc.2023.8.3.483-489
Reena Kumari, B. Yadav, Pankaj Kumar
Objective: To compare two different treatment planning systems (TPSs) for plan quality and to check the feasibility of VMAT TBI on the Elekta linear accelerator ‘Versa HD’. Methods: Ten clinical VMAT TBI plans were replanned in Monaco TPS version 5 for retrospective dosimetric analysis and to check the feasibility of treatment delivery in Elekta Versa HD. A dose of 12 Gy in 6 fractions was prescribed to cover 95% PTV. The OARs were the lungs, kidneys, heart, liver, and brain. Dosimetric optimization and calculation were performed in Monaco TPS with a statistical uncertainty of 1%, 2 mm grid. The chosen criterion for plan evaluation and comparison was based on plan quality, dosimetric indices like conformity and homogeneity index, and OAR doses. The comparison of time for optimization, monitor units, and beam on time was also analyzed. Pre-treatment verification using Octavious phantom and gamma analysis using Low’s method with a dose difference of 3% and distance to agreement 3mm criteria was done. The dosimetry of 2 VMAT TBI plans were compared using Wilcoxon signed rank test. Result: The calculated average maximum and mean doses of the PTV were 14.3321Gy and 12.235Gy for eclipse; and 14.428Gy and 12.198Gy for the Monaco system, respectively. The planning time in Monaco was approx. 4.5–6hrs compared to 14–18hrs for Eclipse TPS. Statistically significant difference was observed between the results of 2 TPSs in terms of monitor units, mean doses to lungs, kidneys, heart, and liver and planning time (P < 0.05). However, calculated p values for HI, CI, and brain for both VMAT TBI plans were not statistically different. Conclusion: The study showed the feasibility of VMAT TBI for VERSA HD as it offers faster, better optimization in a single target compared to the Eclipse.
{"title":"Comparison of Different Dosimetric Indices for Volumetric Arc Modulated Treatment Planning Using 2 Different Treatment Planning Systems: A Feasibility Study for Total Body Irradiation","authors":"Reena Kumari, B. Yadav, Pankaj Kumar","doi":"10.31557/apjcc.2023.8.3.483-489","DOIUrl":"https://doi.org/10.31557/apjcc.2023.8.3.483-489","url":null,"abstract":"Objective: To compare two different treatment planning systems (TPSs) for plan quality and to check the feasibility of VMAT TBI on the Elekta linear accelerator ‘Versa HD’. Methods: Ten clinical VMAT TBI plans were replanned in Monaco TPS version 5 for retrospective dosimetric analysis and to check the feasibility of treatment delivery in Elekta Versa HD. A dose of 12 Gy in 6 fractions was prescribed to cover 95% PTV. The OARs were the lungs, kidneys, heart, liver, and brain. Dosimetric optimization and calculation were performed in Monaco TPS with a statistical uncertainty of 1%, 2 mm grid. The chosen criterion for plan evaluation and comparison was based on plan quality, dosimetric indices like conformity and homogeneity index, and OAR doses. The comparison of time for optimization, monitor units, and beam on time was also analyzed. Pre-treatment verification using Octavious phantom and gamma analysis using Low’s method with a dose difference of 3% and distance to agreement 3mm criteria was done. The dosimetry of 2 VMAT TBI plans were compared using Wilcoxon signed rank test. Result: The calculated average maximum and mean doses of the PTV were 14.3321Gy and 12.235Gy for eclipse; and 14.428Gy and 12.198Gy for the Monaco system, respectively. The planning time in Monaco was approx. 4.5–6hrs compared to 14–18hrs for Eclipse TPS. Statistically significant difference was observed between the results of 2 TPSs in terms of monitor units, mean doses to lungs, kidneys, heart, and liver and planning time (P < 0.05). However, calculated p values for HI, CI, and brain for both VMAT TBI plans were not statistically different. Conclusion: The study showed the feasibility of VMAT TBI for VERSA HD as it offers faster, better optimization in a single target compared to the Eclipse.","PeriodicalId":502165,"journal":{"name":"Asian Pacific Journal of Cancer Care","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139365882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.31557/apjcc.2023.8.3.477-482
Sayoni Bhanja, D. Lahiri, Sanjoy Roy, T. Maji, Palas De
Introduction: Concurrent chemoradiation has shown improvements in local control and survival in various multi-institutional trials and been the standard of care for locally advanced head and neck cancers. Platinum-based chemotherapy has shown the maximum benefit without any significant difference between mono- or polychemotherapy. Despite a general consensus that platinum-containing regimens are optimal, the actual dose schedule remained open questions. Our study aimed to assess the efficacy and toxicity of concurrent weekly cisplatin with radical radiotherapy and compare two different chemotherapy dosing schedules of concurrent chemoradiation in head and neck cancer. Materials and methods: The records of 62 eligible patients of locally advanced (T3-4a, N1-2) squamous cell carcinoma of oropharynx, hypopharynx and larynx registered between 2016 to 2020 at a regional cancer centre in India were analysed from the hospital database after approval of the Institutional Ethical Committee and informed consent taken from all the eligible patients.One group of patients (Group A) received Concurrent Chemo-radiation with injection Cisplatin 40 mg/m2 weekly with Radiotherapy to a dose of 66 Gy delivered in 33 fractions for six & half weeks and the patients of the other group (Group B) received injection Cisplatin 100 mg/m2 in three weekly schedule on Days 1, Day 22 & Day 43 along with the same radiation schedule. Results: There was no significant difference in the baseline characteristics between the two groups (p value≥0.05). Though the complete response occurred more in 3 weekly group compared to weekly cisplatin group at follow up of 6 weeks (67.7% vs 61.3%), 6 months (80.6% vs. 67.7%) and 12 months from the completion of CCRT (78.9% vs 65%), it was not statistically significant (p value≥0.05). No statistically significant differences were found in terms of both the acute toxicities (anaemia, leukopenia, mucositis, dermatitis, UGI toxicities, dysphagia) and late toxicities (laryngeal edema, dryness of mouth and edema of skin of neck) when weekly concurrent chemoradiotherapy was compared to three weekly chemoradiotherapy (p value ≥ 0.05).Conclusion: Weekly chemotherapy regimen can be delivered safely on a day care basis and can be helpful in a set up with limited logistics and considerable patient burden.
{"title":"Comparison of Safety and Efficacy of Two Different Chemotherapy Dosing Schedules Used in Concurrent Chemoradiation of Head and Neck Cancer: A Retrospective Experience from a Tertiary Cancer Care Institute of Eastern India","authors":"Sayoni Bhanja, D. Lahiri, Sanjoy Roy, T. Maji, Palas De","doi":"10.31557/apjcc.2023.8.3.477-482","DOIUrl":"https://doi.org/10.31557/apjcc.2023.8.3.477-482","url":null,"abstract":"Introduction: Concurrent chemoradiation has shown improvements in local control and survival in various multi-institutional trials and been the standard of care for locally advanced head and neck cancers. Platinum-based chemotherapy has shown the maximum benefit without any significant difference between mono- or polychemotherapy. Despite a general consensus that platinum-containing regimens are optimal, the actual dose schedule remained open questions. Our study aimed to assess the efficacy and toxicity of concurrent weekly cisplatin with radical radiotherapy and compare two different chemotherapy dosing schedules of concurrent chemoradiation in head and neck cancer. Materials and methods: The records of 62 eligible patients of locally advanced (T3-4a, N1-2) squamous cell carcinoma of oropharynx, hypopharynx and larynx registered between 2016 to 2020 at a regional cancer centre in India were analysed from the hospital database after approval of the Institutional Ethical Committee and informed consent taken from all the eligible patients.One group of patients (Group A) received Concurrent Chemo-radiation with injection Cisplatin 40 mg/m2 weekly with Radiotherapy to a dose of 66 Gy delivered in 33 fractions for six & half weeks and the patients of the other group (Group B) received injection Cisplatin 100 mg/m2 in three weekly schedule on Days 1, Day 22 & Day 43 along with the same radiation schedule. Results: There was no significant difference in the baseline characteristics between the two groups (p value≥0.05). Though the complete response occurred more in 3 weekly group compared to weekly cisplatin group at follow up of 6 weeks (67.7% vs 61.3%), 6 months (80.6% vs. 67.7%) and 12 months from the completion of CCRT (78.9% vs 65%), it was not statistically significant (p value≥0.05). No statistically significant differences were found in terms of both the acute toxicities (anaemia, leukopenia, mucositis, dermatitis, UGI toxicities, dysphagia) and late toxicities (laryngeal edema, dryness of mouth and edema of skin of neck) when weekly concurrent chemoradiotherapy was compared to three weekly chemoradiotherapy (p value ≥ 0.05).Conclusion: Weekly chemotherapy regimen can be delivered safely on a day care basis and can be helpful in a set up with limited logistics and considerable patient burden.","PeriodicalId":502165,"journal":{"name":"Asian Pacific Journal of Cancer Care","volume":"113 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139364457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.31557/apjcc.2023.8.3.591-598
A. Olayide, Aremu Isiaka, R. Ganiyu, Olatoke Samuel, Akande Halimat, Olasehinde Olalekan, Olaogun Julius, Romanoff Anya
Background: Nigeria has one of the highest age-standardized breast cancer (BC) mortality rates globally and the highest in Africa. Late presentation and diagnosis have been studied extensively as causes of high BC morbidity and mortality, while treatment and outcomes are under-reported. We aggregated data on BC treatment and outcomes in Nigeria to identify gaps in research, challenges, and potential targets for future interventions.Methods: Articles on female BC management in Nigeria published between 2011 and 2021 were reviewed for the prevalence of different treatment modalities and outcomes. The meta-analytical procedure was a random effect model. Results: We identified 15 articles that reported on the treatment and outcomes of 3857 BC patients. The most prevalent treatment modality was chemotherapy alone. The probability of receiving each treatment modality was 85% (95% CI 66-97) for chemotherapy, 62% (95% CI 51-73) for surgery, and 31% (95% CI 8-59) for radiotherapy. Multimodality treatment, including chemotherapy, surgery, and radiation, was administered to 24% (95% CI 10-43) of patients. In studies with available data, nearly half of patients who initiated chemotherapy did not complete the recommended number of doses or received treatments at irregular intervals. The radiotherapy utilization was five times higher when patients received treatment in centers with radiation facilities. Overall survival estimates were 80% at one year, 43% at two years, and 32% at five years. Patients with early-stage (AJCC I/II) disease survived longer, with a 5-year survival difference of 32% compared to patients with late-stage (AJCC III/IV) disease. Patients receiving multimodality therapy survived longer. Three-year survival for patients who received chemotherapy, surgery and radiotherapy was 68%. Whereas it was 43% in patients who received chemotherapy and surgery only. Conclusion: Improving access to complete systemic therapy, surgery, and radiation for breast cancer patients in Nigeria is imperative and should be the target of future interventions.
背景：尼日利亚是全球年龄标准化乳腺癌（BC）死亡率最高的国家之一，也是非洲死亡率最高的国家。作为乳腺癌高发病率和高死亡率的原因，晚诊和诊断已被广泛研究，而治疗和结果却未得到充分报道。我们汇总了尼日利亚有关乳腺癌治疗和结果的数据，以确定研究中的差距、挑战以及未来干预的潜在目标：我们对 2011 年至 2021 年间发表的有关尼日利亚女性 BC 管理的文章进行了审查，以了解不同治疗方式和结果的流行程度。荟萃分析程序采用随机效应模型。结果：我们确定了 15 篇文章，报告了 3857 名 BC 患者的治疗情况和结果。最普遍的治疗方式是单纯化疗。接受每种治疗方式的概率分别为：化疗 85% (95% CI 66-97)，手术 62% (95% CI 51-73)，放疗 31% (95% CI 8-59)。24%（95% CI 10-43）的患者接受了包括化疗、手术和放疗在内的多模式治疗。在有数据可查的研究中，近一半开始接受化疗的患者没有完成推荐的剂量，或接受治疗的时间间隔不规律。在有放射设施的中心接受治疗的患者，放射治疗的使用率要高出五倍。总生存率估计为：一年 80%，两年 43%，五年 32%。早期（AJCC I/II期）患者的存活时间更长，与晚期（AJCC III/IV期）患者相比，5年存活率相差32%。接受多模式疗法的患者存活时间更长。接受化疗、手术和放疗的患者三年存活率为 68%。而仅接受化疗和手术的患者的三年生存率为 43%。结论改善尼日利亚乳腺癌患者接受全面系统治疗、手术和放疗的机会势在必行，应成为未来干预措施的目标。
{"title":"Breast Cancer Treatment and Outcomes in Nigeria: A Systematic Review and Meta-analysis","authors":"A. Olayide, Aremu Isiaka, R. Ganiyu, Olatoke Samuel, Akande Halimat, Olasehinde Olalekan, Olaogun Julius, Romanoff Anya","doi":"10.31557/apjcc.2023.8.3.591-598","DOIUrl":"https://doi.org/10.31557/apjcc.2023.8.3.591-598","url":null,"abstract":"Background: Nigeria has one of the highest age-standardized breast cancer (BC) mortality rates globally and the highest in Africa. Late presentation and diagnosis have been studied extensively as causes of high BC morbidity and mortality, while treatment and outcomes are under-reported. We aggregated data on BC treatment and outcomes in Nigeria to identify gaps in research, challenges, and potential targets for future interventions.Methods: Articles on female BC management in Nigeria published between 2011 and 2021 were reviewed for the prevalence of different treatment modalities and outcomes. The meta-analytical procedure was a random effect model. Results: We identified 15 articles that reported on the treatment and outcomes of 3857 BC patients. The most prevalent treatment modality was chemotherapy alone. The probability of receiving each treatment modality was 85% (95% CI 66-97) for chemotherapy, 62% (95% CI 51-73) for surgery, and 31% (95% CI 8-59) for radiotherapy. Multimodality treatment, including chemotherapy, surgery, and radiation, was administered to 24% (95% CI 10-43) of patients. In studies with available data, nearly half of patients who initiated chemotherapy did not complete the recommended number of doses or received treatments at irregular intervals. The radiotherapy utilization was five times higher when patients received treatment in centers with radiation facilities. Overall survival estimates were 80% at one year, 43% at two years, and 32% at five years. Patients with early-stage (AJCC I/II) disease survived longer, with a 5-year survival difference of 32% compared to patients with late-stage (AJCC III/IV) disease. Patients receiving multimodality therapy survived longer. Three-year survival for patients who received chemotherapy, surgery and radiotherapy was 68%. Whereas it was 43% in patients who received chemotherapy and surgery only. Conclusion: Improving access to complete systemic therapy, surgery, and radiation for breast cancer patients in Nigeria is imperative and should be the target of future interventions.","PeriodicalId":502165,"journal":{"name":"Asian Pacific Journal of Cancer Care","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139364731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Vulvar tumor is a relatively uncommon female genito-urinary tumor, occurs mainly in post-menopausal females. Incidence and patterns of vulvar tumor differ from nation to nation, depending upon multiple factors. The aim of this study was to evaluate epidemiological patterns and clinical profile of vulvar tumor in our institution retrospectively. Methods: This is a retrospective study done in a regional cancer centre of India over10-years period. Data of all vulvar tumor patients, regarding demographic profile and tumor characteristics were collected from record section and reviewed. These data were analysed to get an idea about clinic-epidemiological trends of vulvar malignancy. Results: Total 47-patients with biopsy proven vulvar malignancy were found. Mean age at presentation was 63.4 years. Majority of the patients belonged to rural origin, were post-menopausal and multiparous. Most of them had pruritus as typical presenting symptoms. Histopathologically, squamous cell carcinoma constituted the major bulk. Labia was the commonest site of presentation. Bilateralism was found in one-third among them, inguinal lymphadenopathy and extensive disease were found in five and four patients, respectively. Conclusions: The hallmark about the present article is that it was conducted in the only referral cancer institute of this state. Limited studies from different region of India have published local patients’ data on vulvar tumor. A nationwide collaboration in this regard will help to understand the exact burden of this relatively rare malignancy, epidemiological trends and risk factors as well as an idea about how to manage these patients.
{"title":"Ten Year Experience of Epidemiological Trends and Clinical Pattern of Vulvar Tumor","authors":"Diptajit Paul, Abhishek Soni, Sumit Chatterjee, Abhirup Chanda, Vivek Kaushal, Ashok Chauhan","doi":"10.31557/apjcc.2023.8.3.471-475","DOIUrl":"https://doi.org/10.31557/apjcc.2023.8.3.471-475","url":null,"abstract":"Objectives: Vulvar tumor is a relatively uncommon female genito-urinary tumor, occurs mainly in post-menopausal females. Incidence and patterns of vulvar tumor differ from nation to nation, depending upon multiple factors. The aim of this study was to evaluate epidemiological patterns and clinical profile of vulvar tumor in our institution retrospectively. Methods: This is a retrospective study done in a regional cancer centre of India over10-years period. Data of all vulvar tumor patients, regarding demographic profile and tumor characteristics were collected from record section and reviewed. These data were analysed to get an idea about clinic-epidemiological trends of vulvar malignancy. Results: Total 47-patients with biopsy proven vulvar malignancy were found. Mean age at presentation was 63.4 years. Majority of the patients belonged to rural origin, were post-menopausal and multiparous. Most of them had pruritus as typical presenting symptoms. Histopathologically, squamous cell carcinoma constituted the major bulk. Labia was the commonest site of presentation. Bilateralism was found in one-third among them, inguinal lymphadenopathy and extensive disease were found in five and four patients, respectively. Conclusions: The hallmark about the present article is that it was conducted in the only referral cancer institute of this state. Limited studies from different region of India have published local patients’ data on vulvar tumor. A nationwide collaboration in this regard will help to understand the exact burden of this relatively rare malignancy, epidemiological trends and risk factors as well as an idea about how to manage these patients.","PeriodicalId":502165,"journal":{"name":"Asian Pacific Journal of Cancer Care","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139365647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：